Related Experiment Video
Updated: Jul 10, 2025
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
How to Choose the Right Treatment for Membranous Nephropathy
Luigi Peritore1, Vincenzo Labbozzetta1, Veronica Maressa1
1Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, 98125 Messina, Italy.
Abstract:
Membranous nephropathy is an autoimmune disease affecting the glomeruli and is one of the most common causes of nephrotic syndrome. In the absence of any therapy, 35% of patients develop end-stage renal disease. The discovery of autoantibodies such as phospholipase A2 receptor 1, antithrombospondin and neural epidermal growth factor-like 1 protein has greatly helped us to understand the pathogenesis and enable the diagnosis of this disease and to guide its treatment. Depending on the complications of nephrotic syndrome, patients with this disease receive supportive treatment with diuretics, ACE inhibitors or angiotensin-receptor blockers, lipid-lowering agents and anticoagulants. After assessing the risk of progression of end-stage renal disease, patients receive immunosuppressive therapy with various drugs such as cyclophosphamide, steroids, calcineurin inhibitors or rituximab. Since immunosuppressive drugs can cause life-threatening side effects and up to 30% of patients do not respond to therapy, new therapeutic approaches with drugs such as adrenocorticotropic hormone, belimumab, anti-plasma cell antibodies or complement-guided drugs are currently being tested. However, special attention needs to be paid to the choice of therapy in secondary forms or in specific clinical contexts such as membranous disease in children, pregnant women and patients undergoing kidney transplantation.
Insights
Membranous nephropathy, an autoimmune kidney disease, can lead to end-stage renal disease. Autoantibody discoveries aid diagnosis and treatment, with new therapies under investigation to improve outcomes and manage side effects.
Area of Science:
- Nephrology
- Immunology
- Autoimmune Diseases
Background:
- Membranous nephropathy is a leading cause of nephrotic syndrome.
- Untreated, 35% of patients progress to end-stage renal disease.
- Autoantibodies like phospholipase A2 receptor 1 are key to understanding pathogenesis.
Purpose of the Study:
- To review the current understanding of membranous nephropathy pathogenesis.
- To outline diagnostic approaches based on autoantibody discovery.
- To discuss current and emerging therapeutic strategies.
Main Methods:
- Review of literature on membranous nephropathy.
- Analysis of diagnostic markers including autoantibodies.
- Evaluation of supportive and immunosuppressive treatments.
- Exploration of novel therapeutic agents and clinical contexts.
Main Results:
- Autoantibody identification has advanced diagnosis and treatment guidance.
- Supportive therapies manage nephrotic syndrome complications.
- Immunosuppressive therapy is risk-stratified, but has side effects and variable response rates.
- New treatments like adrenocorticotropic hormone and complement-guided drugs show promise.
Conclusions:
- Advances in understanding autoantibodies have improved membranous nephropathy management.
- Current therapies include supportive care and risk-adapted immunosuppression.
- Novel therapeutic strategies are being investigated to overcome limitations of existing treatments.
- Tailored treatment is crucial for specific populations including children, pregnant women, and transplant recipients.
Related Concept Videos
01:27Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...